BioSpace News Archive

Nevro Corp. today announced that 24-month data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT).

KSQ Therapeutics, Inc. announced today it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279.

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has strengthened its position in the ongoing patent litigations with Pfizer/BioNTech in Germany and the U.S. by expanding the scope of both cases by asserting new intellectual property rights.

electroCore, Inc. announced today that Reletex TM by Reliefband, the first and only FDA cleared non-invasive neuromodulation device available by prescription for nausea and vomiting, will be distributed and billed exclusively by electroCore, Inc. within the Department of Veterans Affairs (VA) and other Federal Supply Schedule (FSS) eligible entities.

BetterLife Pharma Inc. is pleased to highlight the American College of Physician’s guidelines for the treatment of Major Depressive Disorder published recently in Annals of Internal Medicine as an article titled “Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians.”

Akari Therapeutics, Plc today announced updates in the development programs investigating nomacopan in pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).

MaxCyte, Inc. today announced that it will release financial results for the second quarter 2023 after the U.S. market close on Wednesday, August 9th, 2023.

3Daughters announces key senior leadership appointments and the formation of a Scientific Advisory Board to support the development of its lead asset, a highly innovative and frameless intrauterine device for contraception.

Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announced the completion of the previously announced transaction that establishes a strategic relationship with Jefferson Health ( Jefferson ), the largest health system serving the greater Philadelphia and Southern New Jersey.

Calliditas Therapeutics AB announced interim data from the proof-of-concept Phase 2 trial in patients with squamous cell carcinoma of the head and neck with its lead NOX 1 and 4 inhibitor product candidate, setanaxib.